Work

Treating the Underrepresented: Daratumumab in Combination with Cyclophospmaide, Bortezomib and Dexamethasone (Dara-CyBorD) in Newly Diagnosed Multiple Myeloma With Renal Failure

Year: 2026

Type: article

Abstract: BackgroundAcute renal impairment (RI) is a common presentation of newly diagnosed multiple myeloma (NDMM).Patients with RI have been largely excluded from pivotal trials.This study evaluated daratumumab plus CyBorD in NDMM with RI, with emphasis on the underrepresented African American (AA) population.

Source: International Journal of Cancer Care and Delivery

DOI: 10.53876/001a.129796

Authors: Amany Keruakous, Anvay Shah, Inemesit Akpan

Institutions: Augusta University, Augusta University Health

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

OpenAlex ID: W7214321811